Combined contrast enhanced MRI shows promise

May 01, 2006

Combined contrast enhanced (CCE) MRI, in which two contrast agents are used together, permits accurate non-invasive staging of liver fibrosis in non-alcoholic fatty liver disease (NAFLD), according to a new study by researchers from the University of California, San Diego.

For the study, the researchers reviewed 26 patients with NAFLD who underwent CCE MRI. Using a five-point scale, the researchers found that the staging of the NAFLD on CCE MRI closely matched the staging of NAFLD using conventional pathology.

According to the researchers, the prevalence of NAFLD is increasing in western nations and is a major health problem affecting both children and adults. It is a common cause of cirrhosis in American adults and the most common cause in children.

The definitive method of diagnosis and staging is liver biopsy, but it has several limitations, say the researchers. It is invasive, costly, has risks and only samples about 1/50,000th of the liver. "This sampling issue is important because the pathological processes that affect the NAFLD liver are not evenly distributed throughout, so that tiny changes in needle placement will result in potentially large changes in biopsy interpretation. Because of these limitations, alternative methods such as CCE MR need to be developed," said Claude Sirlin, MD, lead author of the study.

"Except for CCE MR, all other experimental techniques rely on surrogate or indirect markers of fibrosis. CCE MR attempts to directly visualize fibrosis by using two contrast agents with complementary mechanisms, iron particles to darken the background liver and gadolinium to brighten the fibrosis," said Dr. Sirlin, "Gadolinium alone and iron particles alone are not adequate for visualization of fibrosis, unless the fibrosis is extremely advanced. However, when given together, the agents show fibrosis with high clarity," he added.

The combined use of two or more complementary contrast agents is uncommon in radiology, according to the researchers. "Partly this is because of the prevailing radiology paradigm and partly this is because most third-party insurers refuse to pay for two contrast agents," said Dr. Sirlin.

Other potential advantages of CCE MR, say the researchers, include that CCE MRI can directly visualize the fibrosis, it has a safety profile higher than biopsy, it can detect liver cancers simultaneously, the procedure is repeatable and the possibility that CCE MRI may be more accurate than any other non-invasive method for assessing liver fibrosis.

The full results of the study will be presented on Monday, May 1, 2006 during the American Roentgen Ray Society Annual Meeting in Vancouver, BC.
-end-
About ARRS
The American Roentgen Ray Society (ARRS) was founded in 1900 and is the oldest radiology society in the U.S Radiologists from all over the world attend the ARRS Annual Meeting to take part in instructional courses, scientific paper presentations, symposiums, new issues forums and scientific and commercial exhibits related to the field of radiology. The ARRS is named after Wilhelm Röentgen, who discovered the x-ray in 1895.

American College of Radiology

Related Biopsy Articles from Brightsurf:

Cerebrospinal fluid as liquid biopsy for characterizing & policing of medulloblastoma
Building on previous research led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published in Nature Communications, show that the analysis of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA), allows for the more precise characterization, molecular diagnosis (including subtyping and risk stratification), and real time tracking of medulloblastoma (MB) - the most prevalent malignant brain tumor in childhood.

Liquid biopsy faster than tissue biopsy, improves time to treat
A pilot study comparing the effects of a liquid biopsy with tissue-based test showed that liquid biopsy turn-around time for results was approximately 10 days faster than the tissue biopsy, according to research presented today at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference.

Study focuses on a different kind of liquid biopsy to detect cancer
In a study published August 13, 2020, in Cell by a team of collaborators from Memorial Sloan Kettering and Weill Cornell Medicine, researchers report that tiny packages of materials released by tumors, called EVPs (extracellular vesicles and particles), may serve as biomarkers for detecting a number of different types of cancer in the early stages.

Chip for liquid biopsy will help to detect prostate cancer
Researchers of Sechenov University together with their colleagues from Australia used the microfluidics technology to develop a device able to isolate cancer cells from urine of patients with prostate cancer.

Hybrid microscope could bring digital biopsy to the clinic
By adding infrared capability to the ubiquitous, standard optical microscope, researchers at the University of Illinois at Urbana-Champaign hope to bring cancer diagnosis into the digital era.

Sentinel lymph node biopsy has no benefits for stage zero breast cancer
Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS) gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has spread, new research by the Yale School of Public Health has found.

CNIO researchers assess melanoma progression with a new liquid biopsy technique
Analysis of extracellular vesicles and circulating DNA from fluid obtained from the drainage implanted after surgery, normally disposed of as medical waste, detects melanoma patients with risk of recurrence and may help doctors decide who should undergo adjuvant therapy The new technique might change the way melanoma patients are followed up.

Contrast-enhanced MRI provides useful findings in discordant core biopsy management
An essential part of breast intervention is the process of assessing concordance between imaging findings and core biopsy results.

3D mammography significantly reduces breast biopsy rates
The use of digital breast tomosynthesis, also known as 3D mammography, may significantly reduce the number of women who undergo breast biopsy for a non-cancerous lesion following an abnormal mammogram, according to a new study.

Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer according to MD Anderson study
A multi-center study led by researchers at The University of Texas MD Anderson Cancer Center revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy.

Read More: Biopsy News and Biopsy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.